Uveitis - Pipeline Review, H1 2012

Uveitis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Uveitis - Pipeline Review, H1 2012', provides an overview of the Uveitis therapeutic pipeline. This report provides information on the therapeutic development for Uveitis , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uveitis . 'Uveitis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Uveitis .
- A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Uveitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Uveitis .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Uveitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Uveitis Therapeutic Products under Development, Key Players in Uveitis Therapeutics, Uveitis Pipeline Overview, Uveitis Pipeline, Uveitis Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uveitis Overview
Therapeutics Development
An Overview of Pipeline Products for Uveitis
Uveitis Therapeutics under Development by Companies
Uveitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Uveitis Therapeutics – Products under Development by Companies
Uveitis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Uveitis Therapeutics Development
Abbott Laboratories
Inovio Biomedical Corporation
Santen Pharmaceutical Co., Ltd.
Lux Biosciences, Inc.
Novartis AG
Enzo Biochem, Inc.
XOMA Ltd.
Aciont Inc.
Artielle ImmunoTherapeutics, Inc.
AnaptysBio, Inc.
SARcode Corporation
Xencor, Inc.
Alimera Sciences, Inc.
ESBATech AG
Icon Bioscience, Inc.
Uveitis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AEB071 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant T Cell Receptor Ligands For Uveitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Steroid For Severe Uveitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DE-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Humira - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VGX-1027 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR1118 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Uveitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xpro1595 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ESBA 105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iluvien - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EGP-437 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Optiquel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Luveniq - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adalimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Humira - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XOMA 052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Raptiva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Humira + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actimmune - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Microplasmin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketorolac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myfortic + Decortin H - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Interferon-Alpha2a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MS-553 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANB004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PA-2612 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Investigative Drug For Chronic Uveitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Uveitis Therapeutics – Drug Profile Updates
Uveitis Therapeutics – Discontinued Products
Uveitis Therapeutics - Dormant Products
Uveitis – Product Development Milestones
Featured News & Press Releases
Jan 05, 2012: EyeGate Pharma Initiates Phase III Study Of EGP-437 In Patients With Anterior Uveitis
Nov 10, 2011: Santen Receives FDA Orphan Drug Status For Sirolimus
Nov 09, 2011: XOMA Expands Gevokizumab Program
Oct 18, 2011: Lux Biosciences Withdraws Marketing Authorization Application For Luveniq
Sep 12, 2011: pSivida Announces Opening Of Investigator-Sponsored Trial For Injectable, Sustained Release FAc Insert For Posterior Uveitis
Sep 08, 2011: Santen Announces EMA Orphan Drug Status For Sirolimus
Jun 24, 2011: Lux Biosciences To Appeal EMA Decision On Luveniq
Apr 14, 2011: CHMP Adopts Positive Opinion For Ozurdex In Non-Infectious Uveitis
Feb 24, 2011: Isotechnika Pharma's Partner, Lux Biosciences, Starts Enrollment In Phase III Uveitis Study
Nov 10, 2010: XOMA Announces Positive XOMA 052 Results In Treatment Of Behcet's Uveitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Uveitis, H1 2012
Products under Development for Uveitis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Abbott Laboratories, H1 2012
Inovio Biomedical Corporation, H1 2012
Santen Pharmaceutical Co., Ltd., H1 2012
Lux Biosciences, Inc., H1 2012
Novartis AG, H1 2012
Enzo Biochem, Inc., H1 2012
XOMA Ltd., H1 2012
Aciont Inc., H1 2012
Artielle ImmunoTherapeutics, Inc., H1 2012
AnaptysBio, Inc., H1 2012
SARcode Corporation, H1 2012
Xencor, Inc., H1 2012
Alimera Sciences, Inc., H1 2012
ESBATech AG, H1 2012
Icon Bioscience, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Uveitis Therapeutics – Drug Profile Updates
Uveitis Therapeutics – Discontinued Products
Uveitis Therapeutics – Dormant Products
Uveitis Therapeutics – Dormant Products (Contd..1)

List of Figures
Number of Products under Development for Uveitis, H1 2012
Products under Development for Uveitis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012